8 episodes

There's a scientific breakthrough in your medicine cabinet. But how did it get there?
 
At a time when medicines are helping us all live longer and healthier lives, this podcast will explore where these taken-for-granted miracles come from, how many of them almost never happened, where the life science ecosystem is taking us next, and most importantly, what it means for patients.
 
From chance meetings that led to new ideas, to risky investments that never pay off, hear from the people behind today's and tomorrow's treatments, vaccines, technologies, devices, and yes, cures.
 
In this golden age of health discovery and innovation fueled by record breaking investment in the life sciences, we'll bring guests who really understand what it means to be Making Medicine.

Making Medicine Incubate Coalition

    • Health & Fitness
    • 5.0 • 14 Ratings

There's a scientific breakthrough in your medicine cabinet. But how did it get there?
 
At a time when medicines are helping us all live longer and healthier lives, this podcast will explore where these taken-for-granted miracles come from, how many of them almost never happened, where the life science ecosystem is taking us next, and most importantly, what it means for patients.
 
From chance meetings that led to new ideas, to risky investments that never pay off, hear from the people behind today's and tomorrow's treatments, vaccines, technologies, devices, and yes, cures.
 
In this golden age of health discovery and innovation fueled by record breaking investment in the life sciences, we'll bring guests who really understand what it means to be Making Medicine.

    The Hidden Cost of Price Control Policies w/ Kirsten Axelsen

    The Hidden Cost of Price Control Policies w/ Kirsten Axelsen

    The price control policies that are being discussed in Congress have the potential to harm innovation in the life science industry. But how, exactly?
    In this episode, we interview Kirsten Axelsen, Senior Advisor at Charles Rivers Associates , about what would change in biopharma if price controls were implemented.
    In this episode, we discuss:

    The close relationship between economy and drug development
    The U.S.’s role in developing over 40% of the world’s new medicines
    The potential reduction of biopharma global revenues by 19%
    What it means globally when 8-15 fewer medicines are made per decade
    Some flaws in the health technology assessment (HTI) regarding clinical trials


    As we continue this journey together, we want to hear from you, the listener. Email John@incubatecoalition.org or Ashlyn@incubatecoalition.org what’s top of mind, what story you want to hear, or what you find interesting!
    To hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform.

    • 25 min
    You Cannot Make Medicine Alone: Relationships & Mentoring w/ Imran Nasrullah

    You Cannot Make Medicine Alone: Relationships & Mentoring w/ Imran Nasrullah

    What goes into a bottle of new medicine is more than the proverbial 15 years and $2 billion. It takes great science, certainly, but it also takes 15 years of relationships.
    No one can make medicine alone, not even Big Pharma. Collaboration, innovation, and industry relationships are key to bringing life-saving medicine to market.
    In this episode, I interview Imran Nasrullah, Vice President & Head, Open Innovation Center North America - East at Bayer Pharmaceuticals, about strengthening relationships within the biotech ecosystem.
    In this episode we discuss:

    The importance of industry relationships in making medicine
    How relationships mitigate the challenge of drug development
    Mentoring options for small, innovative companies
    Relying on partners to actualize different paths to commercialization

    As we continue this journey together, we want to hear from you, the listener. Email John@incubatecoalition.org or Ashlyn@incubatecoalition.org what’s top of mind, what story you want to hear, or what you find interesting!
    To hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform.
    Listening on a desktop & can’t see the links? Just search for Making Medicine in your favorite podcast player. 

    • 27 min
    Improving the Standard of Care w/ Patients in Mind

    Improving the Standard of Care w/ Patients in Mind

    High cost out-of-pocket drugs and obstacles to reduce those prices for patients plague the health industry. With patients in mind, organizations are looking to invest and bring drugs directly to market.
    Gaurav Gupta and Hugo Beekman, Co-Founders of Ascendant BioCapital, join the show to discuss their organization and how they’re focusing on drugs that truly make a difference for patients.

    What we talked about:

    The Founding of Ascendant BioCapital
    The Medical & Investing Backgrounds of the Founders
    Impactful Experiences in the Industry
    Testifying Before Congress & Issues with Out-Of-Pocket Costs
    Importance of Intellectual Property to Biotech

    To hear more interviews like this one, subscribe to the Making Medicine Podcast on Apple Podcasts, Spotify, or your preferred podcast platform.

    • 29 min
    The Truth About Pharmaceuticals w/ Ravi Mehrotra

    The Truth About Pharmaceuticals w/ Ravi Mehrotra

    As it turns out, many perceptions about the pharmaceutical industry are based without all of the facts.


    That’s why we’re sitting down to understand the data with Ravi Mehrotra, Thought Leader and former Senior Managing Director of Biotechnology Equity Research at Evercore ISI.


    What we talked about:
    - Defining WBPI while taking a closer look at the industry
    - The reality that winners pay for all the losers
    - Risk and profitability
    - HR3 legislation
    - Wall Street’s position on the drug pricing debate


    Check out these resources we mentioned during the podcast:
    - HR 3 legislation


    As we continue this new journey together, we would love to hear from you, the listener. Email John@incubatecoalition.org or Ashlyn@incubatecoalition.org what’s top of mind, what story you want to hear, or what you find interesting!


    To hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform.

    • 25 min
    Valuing Inventors & Entrepreneurs: Changing the Dialogue of IP w/ Andrei Iancu

    Valuing Inventors & Entrepreneurs: Changing the Dialogue of IP w/ Andrei Iancu

    Intellectual property (IP) rights have been the driving force behind innovation and entrepreneurship. However, IP has more recently been seen in a negative light.


    Through the COVID-19 Pandemic, vaccine IP rights have come into question: should IP rights be waived when concerning an essential technology?


    Andrei Iancu, Former Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office, joins the podcast to discuss his views and concerns on IP rights:


    What we talked about:
    - The Benefits of IP
    - How Sentiment of IP Has Changed
    - Short, Medium, & Long Term Concerns to Waiving IP Rights
    - Where Concerns Should Be Focused & How to Improve IP


    Check out the resources below for more information:
    - Andrei’s LinkedIn
    - Our host: John Stanford’s LinkedIn
    - www.incubatecoalition.com

    To hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform.

    • 30 min
    AMR: Challenges and Insight w/ Alfonso Chang

    AMR: Challenges and Insight w/ Alfonso Chang

    The fight against Antimicrobial Resistance (AMR) is challenging due to financial, ethical, and legislative issues. Combating infectious disease can prove to be a risky financial investment but much less in comparison to the global impact if solutions are not researched.


    Alfonso Chang is the Managing Director of Relativity Healthcare Partners; he shares insight into the challenges and how to overcome them:
    - Investor Hesitancy

    - Higher clinical and ethical implications

    - Preference of existing therapies over new ones

    - Unintended consequences from lawmakers due to drafted legislative language


    Check out the resources below for more information:

    - Alfonso’s LinkedIn

    - Our host: John Stanford’s LinkedIn


    To hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform.

    • 35 min

Customer Reviews

5.0 out of 5
14 Ratings

14 Ratings

Noel LT ,

Super informative

WOW this is a sexy pod

Top Podcasts In Health & Fitness